Feed / EXEL

Exelixis, Inc.

EXEL

Healthcare · 56.73 +4.0% today

Isolated · not yet confirmedMarket checked 25 Aug, 15:55 GMT-4

Jodie situation report

Exelixis, Inc.'s current read is isolated; its market group is not confirming.

The latest filing evidence is available. 0 of 9 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.

What changed
  • Revenue increased 10.6% versus the comparable filing period.
Company+4.0% todayVolume comparison unavailable
Market group0 of 9 activeBiotechnology · unavailable
Disclosed network0 of 6 confirmingNo filing-linked name is confirming now
What would change this read
  • EXEL's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if EXEL's group or a disclosed connection begins moving with it.

Watch this read

Who this business touches

The relationships behind EXEL

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

TAK7.7% of EXELcustomerMay 5, 2026

During the three months ended March 31, 2026, we recognized $7.7 million in revenues in connection with an $8.0 million commercial milestone payment from Takeda, which was earned upon their achievement of $300.0 million of cumulative net sales of cabozantinib…

MRKMerck & Company, Inc.partnerMay 5, 2026

To further expand our exploration of the clinical potential of zanzalintinib, we entered into a clinical development collaboration with Merck, known as MSD outside of the United States and Canada.

Depended on by

RPRXRoyalty Pharma plcdistributorFeb 11, 2026

Cabometyx/Cometriq – Royalty Receipts from Cabometyx/Cometriq, which is marketed by Exelixis, Ipsen and Takeda, primarily for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, increased by $11.9 million in 2025 as compared to 2024,…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 8 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

EXEL is currently a Early Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.